Iniciar sesión

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can cause a cholinergic rebound and flu-like symptoms. Drug interactions are possible, particularly with MAOIs.

Selective Serotonin Reuptake Inhibitors (SSRIs), such as Fluoxetine (Prozac) and Paroxetine (Zoloft), primarily inhibit serotonin reuptake and treat depression, OCD, anxiety and panic disorder, and bulimia nervosa. Common adverse effects include headache, sweating, gastrointestinal effects, and sexual dysfunction. They can be sedating or activating, depending on the specific drug. Caution is advised when using SSRIs in children and teenagers due to the potential worsening of depression and suicidal thinking.

Serotonin-norepinephrine reuptake Inhibitors (SNRIs), including Venlafaxine (Effexor), Reboxetine (Edronax) and Duloxetine (Cymbalta), inhibit both serotonin and norepinephrine reuptake. They are used for depression, anxiety disorders, pain syndromes, and fibromyalgia. Adverse effects include nausea, headache, sexual dysfunction, dizziness, insomnia, sedation, and constipation. Abrupt discontinuation may cause a discontinuation syndrome.

Del capítulo 15:

article

Now Playing

15.3 : Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Pharmacotherapy of Depression and Anxiety Disorders

193 Vistas

article

15.1 : Depression: Overview

Pharmacotherapy of Depression and Anxiety Disorders

175 Vistas

article

15.2 : Antidepressant Drugs: Overview

Pharmacotherapy of Depression and Anxiety Disorders

282 Vistas

article

15.4 : Antidepressant Drugs: MAOIs and Other Agents

Pharmacotherapy of Depression and Anxiety Disorders

140 Vistas

article

15.5 : Parkinson's Disease: Overview

Pharmacotherapy of Depression and Anxiety Disorders

262 Vistas

article

15.6 : Parkinson's Disease: Treatment

Pharmacotherapy of Depression and Anxiety Disorders

138 Vistas

article

15.7 : Alzheimer's Disease: Overview

Pharmacotherapy of Depression and Anxiety Disorders

277 Vistas

article

15.8 : Alzheimer's Disease: Treatment

Pharmacotherapy of Depression and Anxiety Disorders

107 Vistas

JoVE Logo

Privacidad

Condiciones de uso

Políticas

Investigación

Educación

ACERCA DE JoVE

Copyright © 2025 MyJoVE Corporation. Todos los derechos reservados